Carcinoma of the salivary glands: guidelines and case report of sustained remission with docetaxel.
J Clin Pharm Ther
; 40(1): 116-8, 2015 Feb.
Article
em En
| MEDLINE
| ID: mdl-25302593
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Salivary glands tumours are rare neoplasms for which there are few clinical trials. The most common malignant parotid tumour is the mucoepidermoid carcinoma. High-grade mucoepidermoid carcinomas are highly aggressive tumours. The initial therapy of localized disease is known, but when there is a recurrence, several options are possible and chemotherapy is generally reserved for palliative treatment. We comment on published guidelines and report a case of sustained remission with docetaxel. CASESUMMARY:
Our case concerns a 64-year-old woman with a high-grade mucoepidermoid carcinoma of the parotid gland with local recurrence treated with docetaxel 50 mg/m² every 15 days. After the sixth cycle, a complete remission was observed on CT-scan. The tolerability was excellent. After 2 years of docetaxel, the patient was still in complete remission. WHAT IS NEW ANDCONCLUSION:
Docetaxel is an active drug for the treatment of mucoepidermoid carcinoma of salivary glands. A prospective study should confirm these data.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias das Glândulas Salivares
/
Carcinoma Mucoepidermoide
/
Taxoides
/
Recidiva Local de Neoplasia
/
Antineoplásicos
Tipo de estudo:
Guideline
/
Observational_studies
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Clin Pharm Ther
Ano de publicação:
2015
Tipo de documento:
Article